Gossamer Bio shares are trading higher after a pre‑NDA meeting and FDA minutes outlined a path to a September 2026 NDA filing for seralutinib in PAH. The company also regained global rights to the drug and won shareholder approval for a note exchange and reverse split to bolster its capital structure.